MA56324B1 - Inhibiteurs de l'arginase et leurs procédés d'utilisation - Google Patents

Inhibiteurs de l'arginase et leurs procédés d'utilisation

Info

Publication number
MA56324B1
MA56324B1 MA56324A MA56324A MA56324B1 MA 56324 B1 MA56324 B1 MA 56324B1 MA 56324 A MA56324 A MA 56324A MA 56324 A MA56324 A MA 56324A MA 56324 B1 MA56324 B1 MA 56324B1
Authority
MA
Morocco
Prior art keywords
methods
compounds
formula
arginase inhibitors
arginase
Prior art date
Application number
MA56324A
Other languages
English (en)
French (fr)
Inventor
Maurice Raymond Verschoyle Finlay
Scott Nathan Mlynarski
Tyler Grebe
Sameer Kawatkar
Iain Simpson
Original Assignee
Astrazeneca Ab 151 85 Soedertaelje
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab 151 85 Soedertaelje filed Critical Astrazeneca Ab 151 85 Soedertaelje
Publication of MA56324B1 publication Critical patent/MA56324B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA56324A 2019-02-08 2020-02-07 Inhibiteurs de l'arginase et leurs procédés d'utilisation MA56324B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962802765P 2019-02-08 2019-02-08
PCT/IB2020/050982 WO2020161675A1 (en) 2019-02-08 2020-02-07 Arginase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
MA56324B1 true MA56324B1 (fr) 2023-10-31

Family

ID=69770954

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56324A MA56324B1 (fr) 2019-02-08 2020-02-07 Inhibiteurs de l'arginase et leurs procédés d'utilisation

Country Status (33)

Country Link
US (2) US12435097B2 (https=)
EP (1) EP3921033B1 (https=)
JP (1) JP7526734B2 (https=)
KR (1) KR102759971B1 (https=)
CN (1) CN113395996B (https=)
AU (1) AU2020218651B2 (https=)
BR (1) BR112021015581A2 (https=)
CA (1) CA3127755A1 (https=)
CL (1) CL2021002056A1 (https=)
CO (1) CO2021011039A2 (https=)
CR (1) CR20210463A (https=)
DK (1) DK3921033T3 (https=)
DO (2) DOP2021000166A (https=)
EA (1) EA202192114A1 (https=)
ES (1) ES2960034T3 (https=)
FI (1) FI3921033T3 (https=)
HR (1) HRP20231092T1 (https=)
HU (1) HUE062968T2 (https=)
IL (1) IL285108B2 (https=)
LT (1) LT3921033T (https=)
MA (1) MA56324B1 (https=)
MX (1) MX2021009499A (https=)
MY (1) MY206577A (https=)
PE (1) PE20220280A1 (https=)
PH (1) PH12021551902A1 (https=)
PL (1) PL3921033T3 (https=)
PT (1) PT3921033T (https=)
RS (1) RS64781B1 (https=)
SG (1) SG11202108503PA (https=)
SI (1) SI3921033T1 (https=)
SM (1) SMT202300337T1 (https=)
WO (1) WO2020161675A1 (https=)
ZA (1) ZA202105833B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186134A (zh) * 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
SE0300907D0 (sv) 2003-03-31 2003-03-31 Astrazeneca Ab Novel compounds
LT2389352T (lt) 2009-01-26 2019-06-10 The Trustees Of The University Of Pennsylvania Arginazės inhibitoriai ir naudojimo būdai
SG10201503168VA (en) * 2010-04-22 2015-06-29 Mars Inc Inhibitors of arginase and their therapeutic applications
HRP20160305T1 (hr) 2010-10-26 2016-07-01 Mars, Incorporated Borati kao inhibitori arginaze
WO2013059437A1 (en) 2011-10-19 2013-04-25 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
RU2018138195A (ru) * 2012-12-17 2018-12-18 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US10143699B2 (en) * 2015-06-23 2018-12-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
WO2017175185A1 (en) 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
CN114989205A (zh) 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
CN108794517B (zh) 2017-04-27 2021-03-30 南京谷睿生物科技有限公司 一种精氨酸酶抑制剂及其制备方法与用途
CN117186134A (zh) * 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
EP3765006A4 (en) * 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
CN111770756B (zh) 2018-04-27 2023-03-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
MA53427B1 (fr) * 2018-08-22 2024-06-28 Astrazeneca Ab Inhibiteurs de l'arginase et leurs méthodes d'utilisation

Also Published As

Publication number Publication date
DOP2024000181A (es) 2024-10-15
BR112021015581A2 (pt) 2021-10-05
CN113395996A (zh) 2021-09-14
HUE062968T2 (hu) 2023-12-28
EP3921033A1 (en) 2021-12-15
CO2021011039A2 (es) 2021-09-09
SMT202300337T1 (it) 2023-11-13
JP7526734B2 (ja) 2024-08-01
PT3921033T (pt) 2023-10-11
US20250282800A1 (en) 2025-09-11
IL285108A (en) 2021-09-30
KR102759971B1 (ko) 2025-01-23
ZA202105833B (en) 2025-03-26
IL285108B1 (en) 2024-06-01
FI3921033T3 (fi) 2023-09-15
PL3921033T3 (pl) 2024-01-15
DK3921033T3 (da) 2023-10-16
DOP2021000166A (es) 2021-09-30
MX2021009499A (es) 2021-09-08
JP2022521474A (ja) 2022-04-08
PE20220280A1 (es) 2022-02-25
SI3921033T1 (sl) 2023-11-30
IL285108B2 (en) 2024-10-01
CR20210463A (es) 2021-10-15
SG11202108503PA (en) 2021-09-29
WO2020161675A1 (en) 2020-08-13
ES2960034T3 (es) 2024-02-29
RS64781B1 (sr) 2023-11-30
CL2021002056A1 (es) 2022-03-04
KR20210126044A (ko) 2021-10-19
PH12021551902A1 (en) 2022-08-01
US12435097B2 (en) 2025-10-07
AU2020218651B2 (en) 2023-01-12
US20220106335A1 (en) 2022-04-07
LT3921033T (lt) 2023-09-25
CA3127755A1 (en) 2020-08-13
EA202192114A1 (ru) 2021-12-01
EP3921033B1 (en) 2023-07-26
AU2020218651A1 (en) 2021-09-30
CN113395996B (zh) 2024-05-28
MY206577A (en) 2024-12-24
HRP20231092T1 (hr) 2023-12-22

Similar Documents

Publication Publication Date Title
MA51837B1 (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
RU2581367C2 (ru) Соединения для лечения рака
MA55890B1 (fr) Modulateurs de thr-beta avec un groupe de tête dioxo-1,2,4-triazyl
MA49952B1 (fr) Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations
EP3658538A1 (en) Compounds and compositions for treating conditions associated with nlrp activity
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
WO2017040993A4 (en) Small molecule inhibitors of dyrk1a and uses thereof
EA022420B1 (ru) Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5)
MA38323A1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
MA34450B1 (fr) Dérivés de l'imidazopyridine, procédé pour leur préparation, et leur utilisation thérapeutique
MA47469B1 (fr) Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer
MA45888A1 (fr) Inhibiteurs de tyrosine kinase de bruton
MA31923B1 (fr) Composés de 1,2,4-oxadiazole pour le traitement de maladies auto-immunes
WO2012027481A9 (en) Compounds for treatment of cancer
EA202190586A1 (ru) N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6
GEAP202416543A (en) 4-phenyl-2-(1h-1,2,3-triazol-4-yl)piperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
MA50069B1 (fr) Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique
MA56324B1 (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
JP2021522327A5 (https=)
MA31742B1 (fr) Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
JOP20200263B1 (ar) مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين d1
CA2526989A1 (en) Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
JOP20240217A1 (ar) مشتقات الكوينولين كمُعدِّلات للعضو x2 لمستقبل بروتين g مرتبط بـ mas ومنتجات ذات صلة
JPWO2016017826A1 (ja) キサンチンオキシダーゼ阻害薬
PH12020551297A1 (en) Compounds having s1p5 receptor agonistic activity